Edwards Lifesciences Corporation $EW Shares Bought by Banco Bilbao Vizcaya Argentaria S.A.

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Edwards Lifesciences Corporation by 21.8%, owning 182,269 shares valued at approximately $13.21 million.
• A number of analysts upgraded their ratings on Edwards Lifesciences, with Deutsche Bank raising its price target from $85 to $94 and BTIG Research setting a target of $100.
• Edwards Lifesciences reported earnings per share of $0.67 for the last quarter, exceeding expectations and showcasing a year-over-year revenue increase of 11.9%.

Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 21.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 182,269 shares of the medical research company's stock after buying an additional 32,673 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Edwards Lifesciences were worth $13,214,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Vega Investment Solutions purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $27,000. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at $26,000. SouthState Corp purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $27,000. Rossby Financial LCC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $29,000. Finally, Costello Asset Management INC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.35 during trading on Monday, reaching $81.48. 855,013 shares of the company traded hands, compared to its average volume of 4,496,114. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market cap of $47.84 billion, a P/E ratio of 11.72, a PEG ratio of 3.95 and a beta of 1.08. The firm's fifty day simple moving average is $77.58 and its 200 day simple moving average is $74.72.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same period last year, the firm earned $0.70 EPS. The company's quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,584 shares of company stock worth $1,897,762 in the last ninety days. Company insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. The Goldman Sachs Group restated a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Finally, Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.